NTBL
Notable Labs Inc.
NASDAQ: NTBL · HEALTHCARE · BIOTECHNOLOGY
$0.25
+0.00% today
Updated 2026-05-01
Market cap
$2.39M
P/E ratio
—
P/S ratio
7.65x
EPS (TTM)
$-1.09
Dividend yield
—
52W range
$0 – $0
Volume
2.1M
Notable Labs Inc. (NTBL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | $562000.00 | $922000.00 | $285000.00 | $8000.00 | $310000.00 |
| Revenue growth (YoY) | — | +64.1% | -69.1% | -97.2% | +3775.0% |
| Cost of revenue | $1.44M | $1.59M | $1.62M | $1.16M | $197000.00 |
| Gross profit | $-879000.00 | $-666000.00 | $-1.34M | $-1.15M | $113000.00 |
| Gross margin | -156.4% | -72.2% | -468.8% | -14425.0% | 36.5% |
| R&D | $13.49M | $18.46M | $11.47M | $7.78M | $4.71M |
| SG&A | — | — | $5.73M | $5.16M | $10.06M |
| Operating income | $-20.08M | $-24.48M | $-16.91M | $-12.92M | $-14.66M |
| Operating margin | -3573.3% | -2655.4% | -5934.7% | -161550.0% | -4728.1% |
| EBITDA | $-18.86M | $-23.29M | $-16.59M | $-12.60M | $-14.40M |
| EBITDA margin | -3356.4% | -2525.9% | -5820.4% | -157512.5% | -4645.2% |
| EBIT | $-20.08M | $-24.48M | $-17.84M | $-13.66M | $-14.66M |
| Interest expense | $184000.00 | $105000.00 | — | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-19.40M | $-24.23M | $-16.05M | $-14.41M | $-11.26M |
| Net income growth (YoY) | — | -24.9% | +33.7% | +10.2% | +21.8% |
| Profit margin | -3451.2% | -2627.4% | -5632.3% | -180087.5% | -3633.5% |